BeiGene and Medison announce approval and national reimbursement in Israel for Brukinsa (zanubrutinib) for the treatment of Waldenström's macroglobulinaemia


15 March 2022 - Second regulatory approval for Brukinsa in Israel.

BeiGene and Medison Pharma today announced that the State of Israel Ministry of Health has approved Brukinsa (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinaemia.

Read BeiGene press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Market access , Israel